Net income
−$3.5M
−142.5% vs same quarter last year
EPS, diluted
−$1.98
Operating cash flow
−$2.6M
+28.3% vs same quarter last year
Operating income
−$3.5M
−3.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$28.4M |
| FY24 | - | −$13.2M |
| FY23 | - | −$7.6M |
| FY22 | - | −$20.9M |
| FY21 | - | −$58M |
| FY20 | $0 | −$28.3M |
| FY19 | $0 | −$38.6M |
| FY18 | - | −$259.2M |
| FY17 | $0 | −$144.2M |
| FY16 | $0 | $9.8M |
| FY15 | $27K | −$21.5M |
| FY14 | $61K | −$23.5M |
| FY13 | $368K | −$501K |
| FY12 | $342K | −$5.2M |
| FY11 | $26K | −$3.7M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | - | - |
| FY24 | - | - | - |
| FY23 | - | - | - |
| FY22 | - | - | - |
| FY21 | - | - | - |
| FY20 | - | - | - |
| FY19 | - | - | - |
| FY18 | - | - | - |
| FY17 | - | - | - |
| FY16 | - | - | - |
| FY15 | 100% | −33063% | −79485.2% |
| FY14 | 6.6% | −3927.9% | −38506.6% |
| FY13 | 38.6% | −215.5% | −136.1% |
| FY12 | 72.5% | −1027.5% | −1512% |
| FY11 | −84.6% | −15107.7% | −14230.8% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | −$3.7M |
| FY18 | −$10.7M |
| FY17 | −$5.4M |
| FY16 | −$1.9M |
| FY15 | −$4.7M |
| FY14 | −$1.8M |
| FY13 | −$442K |
| FY12 | −$989K |
| FY11 | −$963K |
- GT Biopharma
- Healthcare median
Show the numbers
| Year | GT Biopharma | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.9% |
| FY20 | - | −62.2% |
| FY19 | - | −46.3% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |
| FY15 | −79485.2% | −38.4% |
| FY14 | −38506.6% | −35.5% |
| FY13 | −136.1% | −37.1% |
| FY12 | −1512% | −29.1% |
| FY11 | −14230.8% | −27.9% |